Predicting Outcomes in Nephrology: Lots of Tools, Limited Uptake: How Do We Move Forward?
- PMID: 38087445
- PMCID: PMC10914199
- DOI: 10.1681/ASN.0000000000000288
Predicting Outcomes in Nephrology: Lots of Tools, Limited Uptake: How Do We Move Forward?
Conflict of interest statement
A. Levin reports Consultancy: Astra Zeneca, Bayer, Boeingher Ingleheim; Chinook Therapeutics; GSK; Janssen, Kidney Foundation of Canada; NIH, Novo Nordisk; Occuryx/Certa, Otsuka, REATA; Research Funding: Astra Zeneca; Boehringer Ingelheim; Canadian Institute of Health Research (CIHR); CITF (Canadian Immunology Task Force), GSK, Health Research BC, Kidney Foundation of Canada; MOH BC, Shared Care BC; Honoraria: AstraZeneca; Bayer; GSK; Janssen; NIH; Advisory or Leadership Role: AstraZeneca, Boehringer Ingelheim, and NIDDK, DSMB for NIDDK, Kidney Precision Medicine, U Washington Kidney Research Institute Scientific Advisory Committee; International Society of Nephrology Research Committee; KRESCENT (Kidney Scientist Education Research National Training Program); GSK, Chinook Therapeutics, BC Renal (Exec Director), Steering Committee Chair CURE Consortium, CADTH, CITF, Co Lead Long Covid Web Grant; PI CanSOLVE CKD; and Other Interests or Relationships: CREDENCE National Coordinator from Janssen, directed to her academic team; NIDDK CURE Chair Steering Committee; International Society of Nephrology; Canadian Society of Nephrology; Kidney Foundation of Canada, Steering Committee ALIGN trial, DSMB Chair RESOLVE Trial (Australian Clinical Trial Network)l ASPIRE Trial (ACTN), Executive Steering Committee AstraZeneca Clinical Trial.
References
-
- Arozullah AM, Daley J, Henderson WG, Khuri SF. Multifactorial risk index for predicting postoperative respiratory failure in men after major noncardiac surgery. The National Veterans Administration Surgical Quality Improvement Program. Ann Surg. 2000;232(2):242–253. doi:10.1097/00000658-200008000-00015 - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
